Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's

Amid all the talk about aducanumab and whether it can be approved in Alzheimer’s disease next year in a classic phoenix from the flames tail, Biogen has served up another trial flop.

In a relatively brief release this morning, the Big Biotech said a midstage test of its experimental med gosuranemab in progressive supranuclear palsy (PSP) failed to hit statistical significance in its primary endpoint.